Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Deferred Taxes (2016 - 2017)

Aptevo Therapeutics (APVO) has disclosed Deferred Taxes for 3 consecutive years, with -$7.5 million as the latest value for Q4 2017.

  • Quarterly Deferred Taxes rose 51.07% to -$7.5 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$23.3 million through Dec 2017, down 47.28% year-over-year, with the annual reading at -$2000.0 for FY2017, 99.99% up from the prior year.
  • Deferred Taxes hit -$7.5 million in Q4 2017 for Aptevo Therapeutics, up from -$15.3 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of -$11000.0 in Q2 2016 to a low of -$15.3 million in Q4 2016.
  • Historically, Deferred Taxes has averaged -$4.0 million across 3 years, with a median of -$575000.0 in 2015.
  • Biggest five-year swings in Deferred Taxes: plummeted 2195.5% in 2016 and later soared 51.07% in 2017.
  • Year by year, Deferred Taxes stood at -$667000.0 in 2015, then tumbled by 2195.5% to -$15.3 million in 2016, then skyrocketed by 51.07% to -$7.5 million in 2017.
  • Business Quant data shows Deferred Taxes for APVO at -$7.5 million in Q4 2017, -$15.3 million in Q4 2016, and -$483000.0 in Q3 2016.